No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
about
Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party.Subcutaneous abatacept for the treatment of rheumatoid arthritis.Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritisTreatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabThe effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Cardiovascular disease and rheumatoid arthritis: an update.Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.Association between anti-TNF-α therapy and all-cause mortalityOral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort studyEffects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Treating to target in rheumatoid arthritis: biologic therapies.Managing cardiovascular risk in patients with chronic inflammatory diseases.A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service.Biologic therapy in psoriasis: perspectives on associated risks and patient management.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Etanercept for treating axial spondyloarthritis.Etanercept for the treatment of non-radiographic axial spondyloarthritis.Golimumab for treatment of axial spondyloarthritis.Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis.Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.Body composition of rheumatoid arthritis patients in the City of Cape Town, South Africa.[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice.How many life years are lost in patients with rheumatoid arthritis? Secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term Australian cohort study.No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan
P2860
Q27335069-00B3453B-2728-49C6-AEDC-37844C97FAF4Q27692117-55DB7AD6-33D3-4A36-B501-9E1AA71F264FQ28709376-69D156EF-646C-49EF-8905-B5D318E1DCF7Q30680371-B2493612-CB84-46C5-AD91-EBAE7B5F54FAQ34658023-F7303AF1-F932-47FE-908D-5DF7CB022246Q35135831-EE0ED7ED-0F56-4958-AC6E-BF399F995A91Q36218375-2BB612C8-05D3-414C-B754-A7CED5139D71Q36220832-58AB088E-7396-4376-892E-EF53FE7F8080Q36590690-BF3DB4A3-481A-4EBB-9935-6A70DC10063DQ37341911-D2ADEACB-001A-41FD-B886-E4780337B602Q37383148-F5B93606-3E4A-4259-BB19-AE0E0723FFA6Q37873493-BE5981D2-B55B-49CD-B6AA-CB1776CA1982Q37954077-DCC7F0E4-8684-4E06-BFF0-4266149E2E9DQ37975943-39092694-6D0D-4600-89EF-C355A5470DF4Q38001590-A1A808A4-FFA4-4263-B1E6-F78309CE9F17Q38020037-B3BA0CB9-DDB9-43C4-9088-B9E2589F7F29Q38145501-E70375E8-981C-4E08-BE18-67A58CEA3BE7Q38176745-E6CF589C-0B13-4B18-A739-FFA52A3F6EB3Q38207759-AF43CACD-6C9F-4D92-AAF2-2A388240655AQ38611064-25B76158-F846-4B13-BDB9-AB2654AD8A74Q38691419-05D312CE-1714-4C21-9BE4-A40A962EE528Q38703849-254BA651-17BE-4D3D-8288-DD7CBD5AB231Q38707718-0B149FA4-73EE-4498-A017-93EF6F354EB5Q40000074-EC38B65B-DE35-4C2A-8EB9-31A0183E0BDBQ40813488-CC40AEB5-4A05-41EF-BB53-E432FE126130Q44477550-5A8CAD27-DA72-4E68-9FD4-3C66ABC86E82Q47272022-630C2C14-C1ED-4B8E-A98D-FF5104090AA7Q49218023-A6B26C9E-24AC-42CE-975C-DB1D5FDF58BFQ50756971-7EADAA27-C164-4988-AC81-4011E7179250Q52887079-DE53B518-D22C-4DE4-8CF2-8D3EAC1284BEQ53650686-64207041-DFAC-47F9-AB65-0AD5E9197F63Q53674421-4644F049-4097-438B-A28F-8907585E5E84Q58204722-B54CA578-24AE-4DBD-9EAA-7E8557E34F94
P2860
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
No evidence of association bet ...... heumatology Biologics Register
@ast
No evidence of association bet ...... heumatology Biologics Register
@en
No evidence of association bet ...... heumatology Biologics Register
@nl
type
label
No evidence of association bet ...... heumatology Biologics Register
@ast
No evidence of association bet ...... heumatology Biologics Register
@en
No evidence of association bet ...... heumatology Biologics Register
@nl
prefLabel
No evidence of association bet ...... heumatology Biologics Register
@ast
No evidence of association bet ...... heumatology Biologics Register
@en
No evidence of association bet ...... heumatology Biologics Register
@nl
P2093
P2860
P50
P356
P1476
No evidence of association bet ...... heumatology Biologics Register
@en
P2093
British Society for Rheumatology Biologics Register Control Centre Consortium
British Society for Rheumatology Biologics Register
Kath D Watson
Kimme L Hyrich
P2860
P304
P356
10.1002/ART.27660
P577
2010-11-01T00:00:00Z